212 related articles for article (PubMed ID: 19075260)
1. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.
Hines SL; Mincey BA; Sloan JA; Thomas SP; Chottiner E; Loprinzi CL; Carlson MD; Atherton PJ; Salim M; Perez EA
J Clin Oncol; 2009 Mar; 27(7):1047-53. PubMed ID: 19075260
[TBL] [Abstract][Full Text] [Related]
2. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
[TBL] [Abstract][Full Text] [Related]
3. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Sestak I; Singh S; Cuzick J; Blake GM; Patel R; Gossiel F; Coleman R; Dowsett M; Forbes JF; Howell A; Eastell R
Lancet Oncol; 2014 Dec; 15(13):1460-1468. PubMed ID: 25456365
[TBL] [Abstract][Full Text] [Related]
4. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
Mok CC; Tong KH; To CH; Siu YP; Ma KM
Osteoporos Int; 2008 Mar; 19(3):357-64. PubMed ID: 18038273
[TBL] [Abstract][Full Text] [Related]
5. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
[TBL] [Abstract][Full Text] [Related]
6. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
Greenspan SL; Brufsky A; Lembersky BC; Bhattacharya R; Vujevich KT; Perera S; Sereika SM; Vogel VG
J Clin Oncol; 2008 Jun; 26(16):2644-52. PubMed ID: 18427147
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
8. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
Markopoulos C; Tzoracoleftherakis E; Polychronis A; Venizelos B; Dafni U; Xepapadakis G; Papadiamantis J; Zobolas V; Misitzis J; Kalogerakos K; Sarantopoulou A; Siasos N; Koukouras D; Antonopoulou Z; Lazarou S; Gogas H
Breast Cancer Res; 2010; 12(2):R24. PubMed ID: 20398352
[TBL] [Abstract][Full Text] [Related]
9. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S; Delmas P
Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
Delmas PD; Balena R; Confravreux E; Hardouin C; Hardy P; Bremond A
J Clin Oncol; 1997 Mar; 15(3):955-62. PubMed ID: 9060533
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.
Hershman DL; McMahon DJ; Crew KD; Cremers S; Irani D; Cucchiara G; Brafman L; Shane E
J Clin Oncol; 2008 Oct; 26(29):4739-45. PubMed ID: 18711172
[TBL] [Abstract][Full Text] [Related]
13. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial.
Waltman NL; Twiss JJ; Ott CD; Gross GJ; Lindsey AM; Moore TE; Berg K; Kupzyk K
Osteoporos Int; 2010 Aug; 21(8):1361-9. PubMed ID: 19802506
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
McClung MR; Miller PD; Brown JP; Zanchetta J; Bolognese MA; Benhamou CL; Balske A; Burgio DE; Sarley J; McCullough LK; Recker RR
Osteoporos Int; 2012 Jan; 23(1):267-76. PubMed ID: 21947137
[TBL] [Abstract][Full Text] [Related]
15. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
[TBL] [Abstract][Full Text] [Related]
16. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
McClung MR; Balske A; Burgio DE; Wenderoth D; Recker RR
Osteoporos Int; 2013 Jan; 24(1):301-10. PubMed ID: 23079690
[TBL] [Abstract][Full Text] [Related]
17. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.
Delmas PD; Benhamou CL; Man Z; Tlustochowicz W; Matzkin E; Eusebio R; Zanchetta J; Olszynski WP; Recker RR; McClung MR
Osteoporos Int; 2008 Jul; 19(7):1039-45. PubMed ID: 18087660
[TBL] [Abstract][Full Text] [Related]
18. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with risedronate and teriparatide in male osteoporosis.
Walker MD; Cusano NE; Sliney J; Romano M; Zhang C; McMahon DJ; Bilezikian JP
Endocrine; 2013 Aug; 44(1):237-46. PubMed ID: 23099796
[TBL] [Abstract][Full Text] [Related]
20. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
